Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
SLN-124 by Silence Therapeutics for Alpha Thalassaemia: Likelihood of Approval
SLN-124 is under clinical development by Silence Therapeutics and currently in Phase I for Alpha Thalassaemia. According to GlobalData, Phase...